Study Summary
A study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r/r AML).
Want to learn more about this trial?
Request More InfoInterventions
CAR-TBIOLOGICAL
A infusion of CLL-1 CAR-T cells following a lymphodepleting chemotherapy regimen.
Study Locations
No locations listed.